Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT06113302

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Led by M.D. Anderson Cancer Center · Updated on 2026-05-04

40

Participants Needed

1

Research Sites

117 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To learn if luspatercept is more effective in helping to reduce the number of blood transfusions needed by patients with LR-MDS.

CONDITIONS

Official Title

A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Diagnosis of myelodysplastic syndromes (MDS) with low or intermediate-1 risk by IPSS or IPSS-R score 4 or less
  • Transfusion dependent patients (at least 2 units of packed red blood cells in past 8 weeks) or transfusion independent with symptomatic anemia
  • Platelet count 100,000 per microliter or less and/or absolute neutrophil count 1,800 per microliter or less
  • Signed informed consent and willingness to participate
  • Adequate liver function (bilirubin 4 times upper limit of normal, AST or ALT 4 times upper limit of normal)
  • Serum creatinine clearance 40 mL/min or higher without end stage renal disease
  • ECOG performance status of 0 to 2
Not Eligible

You will not qualify if you...

  • Active infection not responding to antibiotics
  • Previous treatment with luspatercept or sotarcetept
  • Pregnant or lactating women
  • Patients of reproductive potential unwilling to follow contraception requirements
  • Female patients of reproductive potential without a negative pregnancy test at screening
  • History of active malignancy in past 2 years except certain treated skin or cervical cancers
  • Use of other investigational agents, chemotherapy, radiotherapy, or immunotherapy within 14 days before study treatment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

M D Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

G

Guillermo Garcia-Manero, M D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here